As per the letter attached

11th August, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, G. Block, Bandra Kurla Dalal Street, Complex, Bandra (East), Mumbai 400 001 Mumbai - 400 051 Script Code: 500259 Script Code: LYKALABS Sub: Submission of Revised Press Release on Unaudited Financial Results for the First Quarter ended June 30, 2026 under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dear Sir / Madam, With reference to our earlier submission of the Press Release on the Unaudited Financial Results of the Company for the quarter ended June 30, 2026, filed with the Stock Exchanges on August 10, 2026, we hereby submit a revised Press Release for the same period. This revised submission corrects typographical errors regarding specific financial figures in the original press release. All other data in the release remains unchanged. We kindly request that you take the revised press release on record and update it on your website for the information of members and investors. We deeply regret any inconvenience caused. The above information will also be made available on the website of the Company at www.lykalabs.com Thanking you, Yours faithfully, For Lyka Labs Limited Shailendra Agrawal Company Secretary and Compliance Officer Encl.: as above Press Release Lyka Labs Limited Q1 FY27 Unaudited Financials Results Mumbai, August 10, 2026 : Lyka Labs Limited today announced its unaudited financial results for the first quarter ended 30th June 2026 of the financial year 2026-27 Key Financials of Q1 FY27 ◦ Stanalone Net Total Income up 42.67% at Rs. 4272.79 Lacs. ◦ Consolidated Net Total Income up 26.95% at Rs. 4272.79 Lacs. ◦ Domestic Revenue up 15.91% at Rs. 2652.11 Lacs. ◦ Export Revenue up 68.03 % at Rs. 1483.42 Lacs. ◦ Standalone EBITDA margin @ 11.84% in Q1 FY27 as against 14.16% in Q1 FY26 ◦ Consolidated EBITDA margin @ 11.74% in Q1 FY27 as against 13.07% in Q1 FY26 ◦ Standalone Net Profit up 159.06 % at Rs. 210.03 Lacs. ◦ Consolidated Net Profit up 105.44 % at Rs. 204.66 Lacs. Standalone Q1 FY27 at a glance (Rs. In lacs) Particulars Q1 FY27 Q1 FY26 Growth in % Revenue from Operations 4230.94 2917.64 45.01 EBITDA 5 01.14 4 13.06 21.32 Other Income 41.85 77.34 - 45.89 Finance Cost 100.82 85.14 18.42 Depreciation and amortisation 2 00.96 2 11.18 -4.84 Net Profit after tax 2 10.03 81.07 1 59.06 Consolidated Q1 FY27 at a glance (Rs. In lacs) Particulars Q1 FY27 Q1 FY26 Growth in % Revenue from Operations 4230.94 3302.54 28.11 EBITDA 4 96.57 4 31.73 15.02 Other Income 41.85 63.09 - 33.67 Finance Cost 100.81 85.38 18.07 Depreciation and amortisation 2 00.96 2 11.18 -4.84 Net Profit after tax 2 04.66 99.62 1 05.44 Q1 FY27 Revenue Break-up (Rs. In lacs) Particulars Q1 FY27 Q1 FY26 Growth in % Domestic Branded Formulation 7 37.67 4 54.58 62.27 Branded Veterinary 5 87.35 2 96.90 97.83 P2P 1,327.09 1,536.69 - 13.64 Total Domestic Sales 2,652.11 2,288.17 15.91 Exports Branded Formulation 1,483.42 8 82.85 68.03 Total Export Sales 1,483.42 8 82.85 68.03 Other Operating Income 95.41 131.52 - 27.46 Consolidated Revenue from Operations 4,230.94 3,302.54 28.11 Other Income 41.85 63.09 - 33.67 Consolidated Net Total Income 4,272.79 3,365.63 26.95 About Lyka Labs Limited: Lyka Labs Limited is in the field of Manufacturing & Marketing of Finished Formulations for Human & Animal Healthcare across various therapeutic segments. Shailendra Kumar Agarwal Company Secretary